logo
Plus   Neg
Share
Email

HMS Holdings Boosts FY19 Revenue Outlook - Quick Facts

While reporting financial results for the second quarter on Friday, HMS Holdings Corp. (HMSY), a provider of cost containment solutions, raised its revenue outlook for the full year 2019.

For fiscal 2019, the company raised its revenue outlook to a range of $650 million to $660 million from the prior projection between $640 million and $650 million.

It also now expects net income in the range of $85 million to $90 million, compared to the previous outlook range of $64 million to $70 million.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.17 per share on revenues of $647.27 million for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT